Placental Hypoxia
Placental Hypoxia - Related Videos
07:36
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
0 Views •
Cited by 20 •
2015
Encephalopathy of prematurity encompasses the central nervous system abnormalities associated with injury from preterm birth. This report describes a clinically relevant rat model of in utero transient systemic hypoxia-ischemia and intra-amniotic lipopolysaccharide administration (LPS) that mimics chorioamnionitis, and the related impact of infectious stimuli and placental underperfusion on CNS development.
07:01
Induction and Testing of Hypoxia in Cell Culture
0 Views •
Cited by 247 •
2011
Here we propose simple methods to induce hypoxia in cell cultures and simple tests to evaluate the hypoxic status of the cultures.
12:02
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
0 Views •
Cited by 35 •
2016
This manuscript presents a unique in vitro model of immunopurified human villous cytotrophoblast cells cultured under hypoxia/reoxygenation. This model is suitable to study the protective effects of promising treatments, such as melatonin, on pregnancy complications associated with increased oxidative stress and altered placental function.
12:17
The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
0 Views •
Cited by 18 •
2017
We present a detailed method to study human placental physiology in vivo at term. The method combines blood sampling from the incoming and outgoing vessels on the maternal and fetal sides of the placenta with ultrasound measurements of volume blood flow and placental tissue sampling.
08:01
Induction of Hypoxia in Living Frog and Zebrafish Embryos
0 Views •
Cited by 5 •
2017
We introduce a novel hypoxic chamber system for use with aquatic organisms such as frog and zebrafish embryos. Our system is simple, robust, cost-effective and allows the induction and sustainment of hypoxia in vivo and for up to 48 h. We present 2 reproducible methods to monitor the effectiveness of hypoxia.
FAQs
Low oxygen activates hypoxia-inducible factors, or HIFs, which act as regulatory signals that alter gene expression. These changes influence vascular signaling, trophoblast function, and inflammatory responses within the placenta. Because these pathways connect oxygen availability with placental behavior, they provide a mechanistic framework for studying how abnormal placental conditions may affect pregnancy maintenance and fetal health.
Reduced uteroplacental blood flow can impair oxygen delivery in more than one way: it limits the oxygen reaching the placenta and can reduce the amount available for diffusion across placental tissues. This creates a link between maternal vascular abnormalities and altered placental function, helping explain why vascular disease is examined alongside placental hypoxia in maternal-fetal medicine.
When the oxygen deficit is persistent or severe, the resulting signaling changes may extend beyond a localized placental response. Placental dysfunction can develop, with associations reported for preeclampsia, fetal growth restriction, and other adverse pregnancy outcomes. This distinction matters because research must consider both the initiating oxygen problem and its downstream consequences for the maternal-fetal system.
In maternal-fetal medicine, the process provides a framework for examining how abnormal placental development and maternal vascular disease influence fetal health. Researchers can use it to connect placental-level changes, including altered vascular signaling, trophoblast function, and inflammation, with broader pregnancy outcomes. This makes it relevant to both disease-mechanism studies and investigations of high-risk pregnancies.
Research can focus on the molecular and cellular changes associated with insufficient placental oxygen, including altered gene expression, vascular signaling, trophoblast function, and inflammatory responses. Patterns emerging from these investigations may support biomarker development, giving maternal-fetal medicine researchers candidate indicators to evaluate in relation to placental dysfunction and adverse pregnancy outcomes.
Therapeutic research asks how knowledge of oxygen-responsive signaling and placental dysfunction might be translated into strategies that improve pregnancy outcomes. The available context supports this as a development goal rather than naming a specific treatment: investigations are intended to clarify disease mechanisms first, then guide evaluation of therapeutic strategies for conditions linked to placental hypoxia, including preeclampsia and fetal growth restriction.